Actinogen Medical Ltd

  • IPO date: 2007-10-15
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Company website

Company description

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Financial highlights

Market Capitalization$44.3262 million
P/E Ratio0
P/E Growth Ratio0
Book Value0.007
Dividend Per Share0
Earnings Per Share-0.01
EBITDA-10,660.553
Profit Margin-2.1998
Operating Margin TTM-2.2474
Return on Assets TTM-0.3565
Return on Equity TTM-0.6118
Revenue TTM4,887.935

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
2006-06-30
2007-06-30
2008-06-30 13.639 18 13.639 591.079
2009-06-30 25.589 219 25.589 909.762
2010-06-30 48.411 405 48.411 1,053.626
2011-06-30 58.82 391 58.82 1,109.896
2012-06-30 51.562 427 51.562 1,161.427
2013-06-30 3.102 257 3.102 457.393
2014-06-30 20 0 20 598.182
2015-06-30 49.93 0 153.429 5,577.984
2016-06-30 204.49 0 3,952.943 7,580.266
2017-06-30 155.77 0 1,415.486 4,416.997
2018-06-30 91.9 0 3,300.735 9,562.332
2019-06-30 80.819 80.819 14,470.096
2020-06-30 94.06 8,912.101
2021-06-30 27.09 5,903.911
2022-06-30 41.07 13,173.439
2023-06-30 366.65 15,873.088

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
2006-06-30 44 53 29 495
2007-06-30 48 268 60 1,266
2008-06-30 2,541.159 2,941.506 82.334 4,322.64
2009-06-30 1,849.668 2,007.649 105.419 4,322.64
2010-06-30 1,085.386 1,341.837 173.578 4,322.64
2011-06-30 861.185 1,140.807 94.68 4,920.468
2012-06-30 203.735 465.799 118.809 5,776.407
2013-06-30 112.516 275.672 81.319 5,788.433
2014-06-30 1,127.676 1,261.739 49.927 7,245.614
2015-06-30 9,805.61 15,579.248 222.64 26,254.891
2016-06-30 751.978 12,949.553 824.203 4,025.987 26,308.391
2017-06-30 1,894.605 10,210.025 844.259 2,094.833 26,578.391
2018-06-30 10,003.797 18,026.164 768.253 0 40,438.238
2019-06-30 7,636.601 16,221.941 557.395 0 48,044.606
2020-06-30 5,040.486 11,936.173 1,047.668 86.018 47,924.606
2021-06-30 13,421.653 18,378.402 920.321 71.17 60,054.459
2022-06-30 16,370.283 23,306.351 1,566.474 78.337 76,942.67
2023-06-30 8,460.074 15,208.805 1,801.59 86.933 78,712.128

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
2006-06-30
2007-06-30 26.568
2008-06-30 -435.658 -397.223 2,514.591 26.568 2,541.159
2009-06-30 -926.942 -546.874 -691.491 2,541.159 1,849.668
2010-06-30 -737.471 -727.365 -764.282 1,849.668 1,085.386
2011-06-30 -742.38 -805.704 -224.201 1,085.386 861.185
2012-06-30 -1,529.156 -823.941 -657.45 861.185 203.735
2013-06-30 -164.663 -125.565 -91.219 203.735 112.516
2014-06-30 -440.222 -437.837 1,015.16 112.516 1,127.676
2015-06-30 -5,431.009 -3,719.789 8,677.934 1,127.676 9,805.61
2016-06-30 -3,633.758 -5,039.139 -9,053.632 9,805.61 751.978 0
2017-06-30 -3,190.338 -1,108.799 1,142.627 751.978 1,894.605 0
2018-06-30 -6,230.609 -7,911.052 8,109.192 1,894.605 10,003.797
2019-06-30 -10,364.582 -10,498.298 -2,260.159 9,896.76 7,636.601
2020-06-30 -5,359.411 -2,855.613 -2,596.115 7,636.601 5,040.486
2021-06-30 -3,937.385 -1,723.902 8,381.167 5,040.486 13,421.653
2022-06-30 -9,515.849 -9,115.18 2,948.63 13,421.653 16,370.283
2023-06-30 -10,752.27 -8,698.24 -7,910.209 16,370.283 8,460.074